# A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

> **NCT00765115** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 27 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** LY450139
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00765115
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2008-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765115, "A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00765115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*